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Reply to Comment Letter 1 
Johanna Sandlund
1




Singulex, Inc 3 
 2
Leeds Teaching Hospitals NHS Trust and University of Leeds 4 
 5 
To the Editor 6 
In a Letter to the Editor, Tenover et al suggest that on-label testing with nucleic acid amplification tests 7 
(NAATs) for the diagnosis of Clostridioides difficile infection (CDI) is discussed, to put toxin testing in 8 
perspective. The authors argue that guidelines from the Infectious Diseases Society of American- Society 9 
for Healthcare Epidemiology of America (IDSA-SHEA)(1), the American Society for Microbiology (ASM) 10 
(2), and the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) (3), “all make it 11 
clear that NAATs play an essential role in the laboratory diagnosis of CDI.” This statement is potentially 12 
misleading. Firstly, the ESCMID guidelines state that “using NAAT as a stand-alone test and relying on 13 
clinical symptoms to discern patients with CDI from asymptomatic carriers is not an optimal approach: 14 
patients colonized by a toxigenic C. difficile strain may very well develop diarrhea due to other causes 15 
(3).” Secondly, the systematic review from ASM evaluated performance compared to detection of C. 16 
difficile organism/toxin/toxin and not clinical diagnosis (2). However, this systematic review somewhat 17 
disingenuously evaluated only testing methods and algorithms including NAAT, and excluded key studies 18 
that have demonstrated the clinical value of toxin based testing (4, 5). Tenover et al claim that ASM 19 
guidelines “endorses a role for stand-alone NAATs for CDI,” while the ASM authors state that the use of 20 
NAAT alone is recommended best practice “for the detection of the C. difficile toxin gene or organism 21 
(2).” The two statements are certainly not synonymous. Thirdly, the IDSA-SHEA guidelines do 22 
recommend that NAAT can be used alone, but only when there are pre-agreed institutional criteria for 23 
patient stool submission (weak recommendation, low quality of evidence). These guidelines also clearly 24 
recommend an algorithm approach to CDI diagnosis that includes toxin testing. The clinical criteria, 25 
unexplained and new-onset ≥3 unformed stools in 24 hours in patients not receiving laxatives, are 26 
discussed in the guidelines: “some of these conditions and interventions associated with diarrhea in 27 
their own right, […], have been shown to have increased risk of CDI. So, in practice it is difficult to 28 
exclude the possibility of CDI on clinical grounds alone in a patient with new-onset or worsened diarrhea 29 
(1).”  30 
 31 
Tenover et al agree that using NAAT for the diagnosis of CDI leads to overdiagnosis, but only if the 32 
clinical criteria for testing are not met. The authors further argue that any diagnostic C. difficile assay can 33 
be positive in asymptomatic carriers. In a recent study, it was shown that the proportion of CDI 34 
overdiagnosis was over three times higher in NAAT+/toxin- than in NAAT+/toxin+ patients when an 35 
ultrasensitive toxin assays was used for CDI diagnosis, in an institution where rigorous stool-submission 36 
criteria were recently successfully set in place (6, 7). CDI is a toxin-mediated disease and, although it has 37 
been known for decades that toxin-producing strains can be present in asymptomatic carriers (8, 9), 38 
presence of toxins better correlate with disease and outcome than presence of toxin genes (4–6). 39 
Hospital-onset diarrhea is a common condition and importantly a recent large study showed that the 40 
majority (85%) have multiple possible causes (median 3; IQR 2-5) (10). Thus, reliance on NAAT alone for 41 
the diagnosis of CDI will still lead to overdiagnosis even if clinical criteria are used to guide who/when to 42 
test. 43 
A number of NAAT qualities are highlighted in the Letter: speed, sensitivity, high negative predictive 44 
value, and cost-effectiveness when used appropriately (although the latter can be debated). The authors 45 
have, rightfully so, left out high clinical specificity and high positive predictive value, both critical 46 
components of any diagnostic test. Surprisingly, Tenover et al close their Letter with the statement “we 47 
simply note that three recent guidelines support the value of NAATs for diagnosing CDI, while none 48 
indicate a role of ‘ultrasensitive’ toxin tests.” Notably, however, an ultrasensitive toxin test was not 49 
commercially available at the time of publication of these guidelines, making such a recommendation 50 
impossible.   51 
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